Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,752 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT06822829Recruiting
Study of lymphoma that returned as slow-growing type
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Reggio EmiliaAges 18 years+ - NCT06395870RecruitingPhase 1
Dual-target cell therapy for returning B-cell lymphoma
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Hefei, AnhuiAges 18–75 - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT06047197RecruitingPhase 1
RC19D2 cell therapy for advanced large B-cell lymphoma
This trial tests a new cell therapy called RC19D2 for people with diffuse large B-cell lymphoma that has not responded to standard treatments. The therapy uses your own immune cells that are modified to target and kill cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06651853RecruitingPhase 2
Radiation therapy with lenalidomide and glofitamab for DLBCL
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
Xiamen, FujianAges 18 years+ - NCT06552559RecruitingPhase 1/Phase 2
Selinexor plus ICE chemo for brain-involved B-cell lymphoma
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
SeoulAges 18 years+ - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for post-transplant lymphoma that didn't respond to treatment
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT04532281RecruitingEarly Phase 1
CD19 CAR-T therapy for relapsed or resistant blood cancers
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hangzhou, ZhejiangAges Any age - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,752 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.